Alport syndrome
Conditions
Interventions
ERA group:The experimental group received ambrisentan 5 mg qd (from Day 0 to Month 6).
Placebo group:The placebo group received placebo 5 mg qd (from Day 0 to Month 6).
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old=0.5g/d; 5. eGFR>25ml/min/1.73m^2 (calculated by CKD-EPI formula); 6. Chest CT images within half a year did not show pulmonary fibrosis; 7. Agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Received immunosuppressive therapy (hormones, cyclosporine, hydroxychloroquine, tacrolimus, mycophenolate mofetil, tripterygium vine) in the past 3 months; 2. Combined with other glomerular diseases; 3. Those with a history of idiopathic pulmonary fibrosis; 4. Hypotension (SBP twice the upper limit of normal); 6. History of malignant tumors, organ transplantation or chronic liver disease; 7. Dialysis patients; 8. Those who have allergic reactions or angioedema to Amrisentan; 9. Life expectancy less than 1 year; 10. Patients during pregnancy and lactation; 11. Female patients who are preparing for pregnancy during the study; 12. Participated in other drug clinical studies in 1 month before screening; 13. Those who have lost the ability to act independently; 14. The investigator believes that it is not suitable to participate in clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24hUTP; | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR;UACR; | — |
Countries
China
Contacts
Public ContactXujie Zhou
Peking University First Hospital
Outcome results
None listed